Physician profile
Paul Arias
NPI 1255482022
$1,206.68
in general payments reported to CMS, 2019-2025
14 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.70 · 2020: $113 · 2021: $228 · 2022: $331 · 2023: $261 · 2024: $90.42 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449 · Education: $13.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $448.66 |
| Education | $13.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $419.76 | 2019-2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $247.38 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $75.57 | 2020-2023 | Verquvo, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.42 | 2019-2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $74.16 | 2022-2023 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $65.13 | 2019-2022 | |
| Ardelyx, INC. | $47.98 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $43.11 | 2024-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $43.00 | 2021-2023 | Acthar |
| Novo Nordisk INC | $39.77 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $38.63 | 2021-2023 | Rayaldee |
| Hikma Pharmaceuticals USA | $13.71 | 2021 | |
| Horizon Therapeutics Plc | $12.97 | 2020 | |
| Allergan, INC. | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Arias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.